Journal Scans
Identification of an Alternative CD20 Transcript Variant in B Cell Malignancies Coding for a Novel Protein Associated to Rituximab Resistance
mRNA Splicing of CD20 Codes for Rituximab-Resistance Protein
C Henry, M Deschamps, P-S Rohrlich, J-R Pallandre, J-P Rémy-Martin, M Callanan, A Traverse-Glehen, C GrandClément, F Garnache-Ottou, R Gressin, E Deconinck, G Salles, E Robinet, P Tiberghien, C Borg, C Ferrand
20100020
2010 Jan 20
Blood
Identification of an Alternative CD20 Transcript Variant in B Cell Malignancies Coding for a Novel Protein Associated to Rituximab Resistance
Blood. 2010 Jan 20; Epub ahead of print, C Henry, M Deschamps, P-S Rohrlich, J-R Pallandre, J-P Rémy-Martin, M Callanan, A Traverse-Glehen, C GrandClément, F Garnache-Ottou, R Gressin, E Deconinck, G Salles, E Robinet, P Tiberghien, C Borg, C Ferrand
TAKE-HOME MESSAGE
Abstract
Abstract
Human CD20 is a B-cell lineage-specific marker expressed by normal and leukemic B cells from the preB to the plasma-cell stages and is a target for rituximab (RTX) immunotherapy. A CD20 reverse-transcriptase-polymerase chain reaction on B-cell lines cDNA yielded a short PCR product ( ΔCD20) corresponding to a spliced mRNA transcript linking the exon3 and exon7 ends. We established here that this novel, alternatively spliced CD20 transcript is expressed and detectable at various levels in leukemic,...
